Mallinckrodt has announced the commercial launch of Pennsaid 2% (w/w), a treatment for pain from knee osteoarthritis.


Mallinckrodt, Pennsaid 2%, knee osteoarthritis, Hugh O'Neill, topical nonsteroidal anti-inflammatory drug, NSAID








































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Mallinckrodt releases Pennsaid 2%

February 10th, 2014

ST. LOUIS – Mallinckrodt has announced the commercial launch of Pennsaid 2% (w/w), a treatment for pain from knee osteoarthritis.

"We are excited to make Pennsaid 2% available for patients who suffer from pain associated with osteoarthritis of the knee," Hugh O’Neill, senior vice president and president of U.S. specialty pharmaceuticals for Mallinckrodt, said in a statement on Monday. "This launch is the result of our continued commitment as a company to bringing additional NSAID treatment options to the market."

A topical nonsteroidal anti-inflammatory drug (NSAID), Pennsaid 2% was approved by the Food and Drug Administration in mid-January.

U.S. sales and marketing rights for Pennsaid 2% are licensed to Mallinckrodt by Nuvo Research Inc.

Advertisement